By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Sutro Biopharma 

310 Utah Avenue
Suite 150
South San Francisco  California  94080  U.S.A.
Phone: 650-392-8412 Fax: 650-872-8924


Sutro Biopharma, Inc. develops best-in-class antibody-drug conjugate and multi-specific antibody-based therapeutics for cancer therapy. Sutro’s discovery and development efforts are driven by the Xpress CF™ platform, a biochemical synthesis system that enables rapid and systematic evaluation of protein structure-activity relationships. Sutro’s make-test cycle for hundreds of protein variants, including those incorporating non-natural amino acids, takes approximately two weeks, enabling broader and deeper biologics discovery and development efforts than can be accomplished with current cell-based expression technologies. Sutro’s technology platform allows production of proteins by bypassing the cell completely, cutting the pre-clinical development period by several months and can be done on any scale in just 8-10 hours.

Once identified, production of protein drug candidates can be rapidly and predictably scaled in Sutro’s cGMP manufacturing facility located in San Carlos, CA. Importantly, Xpress CF™ was nominated for best scientific innovation by World ADC in 2014 and Sutro Biopharma was named one of FierceBiotech’s Fierce 15 in 2014.

In addition to developing its own drug pipeline, Sutro Biopharma is collaborating with select pharmaceutical and biotech companies to discover and develop novel therapeutics. Last year, Sutro partnered with both Celgene and EMD Serono. This second partnership with Celgene is a multi-year collaboration focused on immuno-oncology and is valued at over $1 Billion. In the agreement, Celgene has an exclusive option to acquire Sutro. The deal with EMD Serono is a $300M+ collaboration to discover and develop novel antibody-drug conjugates for several targets in the field of oncology.

Key Management:

• William J. Newell, JD, CEO
• Trevor Hallam, PhD, Chief Scientific Officer
• Ed Albini, Chief Financial Officer
• Henry Heinsohn, VP Development & Manufacturing
• Aaron Sato, PhD, VP Research
• Nicki Vasquez, PhD, VP Alliance/Project Management

Interested in joining Sutro? Check us out on Linkedin @

Key Statistics

Ownership: Private

Web Site: Sutro Biopharma
Employees: 80


Company News
New Evidence Of Sutro Biopharma ADC's Potency In Human Tumor Xenografts 7/17/2017 9:03:01 AM
Sutro Biopharma Appoints Lobacki As Director; Leonard, Krishnan & Levy As Advisors 4/27/2017 8:24:51 AM
Sutro Biopharma ADC Targeting CD74 Eradicates B-Cell Hematologic Malignancy, Prolongs Survival In Tumor Models 4/3/2017 9:43:19 AM
Sutro Biopharma ADC Targeting CD74 Exhibits Potent Anti-Tumor Activity In Multiple Malignant Cell Lines And Animal Models Of Non-Hodgkin Lymphoma And Multiple Myeloma 12/6/2016 10:48:11 AM
Sutro Biopharma ADCs Targeting CD74 Suppress Tumors In Multiple Malignant Cell Lines And Animal Models Of Multiple Myeloma And Non-Hodgkin Lymphoma 9/19/2016 8:16:57 AM
Sutro Biopharma Marks Important Progress -- Receives Two Milestone Payments From Celgene (CELG) 9/7/2016 11:49:24 AM
Sutro Biopharma Appoints Shabbir T. Anik Chief Technical Operations Officer 6/1/2016 6:46:44 AM
Sutro Biopharma Expands Senior Leadership Team With Addition Of Chief Medical Officer And VP Of Translational Pharmacology And Preclinical Development 3/9/2016 8:12:26 AM
Sutro Biopharma Receives The Pantheon 2015 DiNA Outstanding Partner Award By The California Life Sciences Association 11/18/2015 9:26:24 AM
Sutro Biopharma Appoints Nicki Vasquez, Ph.D. As VP Of Alliance And Project Management 8/4/2015 7:30:58 AM